Ombretta Annibali
Overview
Explore the profile of Ombretta Annibali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
453
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cox M, Caridi M, Patirelis A, Del Giudice I, Pulsoni A, Renzi D, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075612
: The treatment of older patients with classic Hodgkin lymphoma (eHL) remains a challenge. : This study reports the first real-life survey of eHL treated with contemporary therapies in Italy....
2.
Castellino A, Comba L, Bertolotti L, Boccomini C, Clerico M, Nicoli P, et al.
Ann Hematol
. 2025 Mar;
PMID: 40074837
The SARS-CoV2 pandemic has posed unprecedented challenges between temporary or permanent discontinuation of immunosuppressive treatment to protect patients, or disease control prioritization by not interrupting treatment. Maintenance treatment with anti-CD20...
3.
Martino E, Pitino A, Offidani M, Pepa R, Gozzetti A, Bongarzoni V, et al.
Haematologica
. 2025 Mar;
PMID: 40045883
Not available.
4.
Tomarchio V, Crescenzi A, Tafuri M, Verri M, Di Cecca M, Rigacci L, et al.
Expert Rev Hematol
. 2025 Feb;
PMID: 39987500
Introduction: Myeloma genesis is a very complex mechanism in which the interaction between plasma cells and microenvironments with immune cells, cytokines and chemokines have a central role. In the last...
5.
Martino E, Derudas D, Rossi E, Stefanoni P, Mangiacavalli S, Zamagni E, et al.
Hematol Oncol
. 2025 Feb;
43(2):e70042.
PMID: 39898517
This multicenter real-world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara-R). The majority were under...
6.
Bavieri A, Nizzoli M, Tucci A, Zilioli V, Olivieri J, Bianchi B, et al.
Hemasphere
. 2024 Dec;
8(12):e70049.
PMID: 39698333
No abstract available.
7.
Martino E, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, et al.
Haematologica
. 2024 Nov;
PMID: 39605207
Not available.
8.
Mallio C, Tomarchio V, Pulcini F, Verducci E, Bernetti C, Tafuri M, et al.
Hematol Rep
. 2024 Oct;
16(4):624-635.
PMID: 39449304
Background: The aim of this study was to evaluate the impact of trabecular attenuation of the L1 vertebral body in low-dose CT in adult patients with multiple myeloma (MM), smoldering...
9.
Annibali O, Merli M, Minoia C, Mancuso S, Guarini A, Gini G
Leuk Lymphoma
. 2024 Sep;
66(1):109-114.
PMID: 39291918
Patient diagnosed with lymphoma presents a greater risk of infection, mainly if undergoing anti-CD20 therapy, splenectomized, hypogammaglobulinemic. They can therefore benefit from a vaccination program, especially in the watchful waiting...
10.
Cammalleri V, de Luca V, Antonelli G, Annibali O, Nusca A, Mega S, et al.
Rev Cardiovasc Med
. 2024 Jul;
23(10):345.
PMID: 39077150
Cardiac amyloidosis (CA) manifests as infiltrative cardiomyopathy with a hypertrophic pattern, usually presenting with heart failure with a preserved ejection fraction. In addition, degenerative valvular heart disease, particularly severe aortic...